Next Generation Sequencing is rapidly evolving the landscape of clinical research through new, data-driven approaches that require deeper analysis. But much like opening a flood gate, the total power of possibilities NGS brings can be overwhelming. With so much more data to manually sift through, it can take precious time before any actionable insights are gained from sequencing. By leveraging expertly curated evidence, powered by JAX-CKB, and SOPHiA GENETICS’ patented algorithms through the SOPHiA DDM platform, users can then use OncoPortal™ Plus to accurately identify clinical associations and actionable biomarker profiles. With new customizable reporting templates, any lab can prepare state-of-the-art comprehensive genomic reports to match the preferences of their clients and oncologists.
Actionable biomarker assessment
There’s a lot that can be learned from analysis that goes beyond simply mining a sample for all available information. We must consider how we review that large mass of data to determine what is important. Think of it like observing a painting at a museum. If you were to only slowly scan the corners of the Mona Lisa, you may miss the subtly in her smile or how she seems to glow in comparison to the background. Like art, some things are better observed with all minute angles taken into much larger consideration.
The larger portrait an analysis paints must be viewed through multiple filters, like lenses with varying scopes of biomarker assessment and scrutiny. For example, a single variant discovered among the data may indicate a possible treatment option, but another biomarker in that sample may contradict its usefulness as a viable therapy. By only offering a micro-glimpse into individual datapoints, traditional/manual reporting is not automatically showing the macro-effect of what that data means as a whole.
Through molecular profiling, OncoPortal™ Plus doesn’t just identify individual variants, it works with you to better classify and interpret co-occurring biomarkers, including wild-type genes, that give researchers a wider, more accurate portrait of options in reporting. This allows for better decision making, eliminating redundant entries that could lead decision-makers down the wrong paths and waste valuable time.
Flexible push-button reporting
With AMP/ASCO/CAP classification of biomarkers, including Tier III (VUS), OncoPortal Plus combines your (secondary) analysis results with the SOPHiA DDM platform knowledge base to allow you to prepare genomic reports with detailed biomarker descriptions. The new, intuitive format displays actionable biomarkers, approved therapies, and a summary of relevant biomarkers that may play further roles in decision making. All of this can be customized with templates that meet the needs of the individual user.
Custom report templates in the Template Manager give plenty of room for molecular labs to configure their genomic reports to match the various needs and preferences of their clients. Combining the power of the SOPHiA DDM Platform with OncoPortal™ Plus then helps the user to interpret genomic findings for your final reports. Once this feature has been utilized in-house, much of the work can be done with just a click, avoiding having to rely on send-out reporting.
Our new offering comes with constantly improved security and technical support, getting you up and running to quickly match your compliance needs. If you’d like to learn more about our products or catch a demo with an expert, just click here and contact us today.
